TargetCancer Foundation

We are truly honored to be named an inaugural Illumina, Inc. Corporate Foundation IMPACT grant program recipient!

The IMPACT grant program aims to address gaps that prevent cancer patients from accessing genomic testing, and we will use this funding to support TCF-001 TRACK, our fully decentralized clinical trial that brings biomarker testing and expert precision medicine recommendations directly to patients with rare cancers or cancers of unknown primary across the US. 🧬

In addition to funding, the IMPACT grant program brings awardees together to share insights and learn from one another. We are grateful for this opportunity, and we look forward to collaborating with our fellow awardees to improve access to genomic testing.

To learn more about the IMPACT grant program and our fellow recipients, read the article linked below:

8 Cancer organizations receive grants to expand access to genomic testing Meet the awardees of Illumina Corporate Foundation’s first IMPACT grants

The final putt has dropped! ⛳️

We are incredibly proud of our Golf Fights Cancer Golf Marathon team members, Ryan Marsh and Kevin Kershaw, for taking big swings against rare cancers at Juniper Hill Golf Course yesterday.🏌️‍♂️💥

A special thank you goes out to our VIP caddy, TCF Board Chair Colin Carey, for hitting the links with our team, and to Golf Fights Cancer for inviting us to be a part of such a meaningful event.

We are deeply grateful to everyone who has already chipped in to support Ryan and Kevin. The final leaderboard isn't locked in just yet - which means there is still time for you to help them drive home their fundraising goals! 💚

Click here to make a donation and show your support:
https://secure.qgiv.com/event/negolfmarathon/

has been an incredible experience so far! ✨

We're grateful to everyone who stopped by our poster presentation to learn about the latest genomic data generated by TCF-001 TRACK, our fully decentralized clinical trial that brings biomarker testing and expert precision medicine recommendations directly to patients with rare cancers or cancers of unknown primary across the US. 🧬

📖 Full Abstract: https://www.asco.org/abstracts-presentations/263246
🔗 TRACK Website: https://www.targetcancer.org/track

We can't wait to share more highlights from the 2026 American Society of Clinical Oncology Annual Meeting! Stay tuned.

Our team is attending the 2026 American Society of Clinical Oncology Annual Meeting this weekend!

If you're at , come to our poster presentation and dive into the latest TRACK clinical trial data with our study team:

📍 Poster Board 284
🗓️ Saturday, May 30
🕜 Time: 1:30 PM - 4:30 PM CT
📖 Full Abstract: www.asco.org/abstracts-presentations/263246
🔗 TRACK Website: www.targetcancer.org/track

Happy opening day to ASCO!

The 2026 American Society of Clinical Oncology Annual Meeting is more than a conference – it’s considered *the* place to be for groundbreaking science, innovation, and connection that come together to shape the future of cancer care, and it starts TODAY throughout the McCormick Place South, North, West, and Lakeside Center buildings and the Arie Crown Theater.

The stage is set, our campus teams are ready, and we cannot wait to hear from attendees about the networking and connections created at this year's Annual Meeting.

: Meet the Mintz Project Analysts!

As part of our longstanding relationship, Mintz assigns two Project Analysts (PAs) to TCF each year to provide critical volunteer support for our annual fundraising events.

This year, Shruthi and Emma spent months securing donations and organizing our silent auction leading up to A Night to Strike Out Rare Cancer at Fenway Park. On the night of the event, they coordinated their fellow PAs to expertly handle check-in, check-out, and everything in between.

We're incredibly grateful to Shruthi, Emma, Grace, Jessica, Jordyn, Judy, Miya, Sneha, and Wish for your incredible dedication. We couldn't do this without you! 🙌

Thank you, Mintz, for partnering with us to support the rare cancer community! 💚

The wait is over! 🎉

Our full abstract, "Fast-TRACKing precision oncology for rare cancers: A national decentralized trial offering comprehensive genomic profiling and a molecular tumor board," is now available to view online.

Our team will be at from May 29 - June 2 to share the latest data generated through our TCF-001 TRACK clinical trial. We'd love to see you there! Please visit our poster or reach out to schedule a meeting with us.

View our full abstract here: https://www.asco.org/abstracts-presentations/263246

📸 by American Society of Clinical Oncology

abstracts have dropped! 🎉 Get inspired by the wealth of new oncology knowledge contained in the 7,000+ abstracts that will be presented or published now available, detailing the science that aims to transform cancer care and outcomes for patients globally: https://bit.ly/4f0s5Ey

Behind every rare cancer breakthrough is a dedicated community. 🧬✨

On , we celebrate the patients and research teams driving scientific innovation forward.

To the rare cancer patients who participate in clinical trials to advance science for themselves and future generations, and to our incredible TRACK staff, clinicians, and researchers working behind the scenes to make remote-access clinical trials a reality: Thank you!

If you or a loved one are seeking clear, accessible information to help navigate rare cancer clinical trials, explore our resources and download our free educational booklet: https://targetcancer.short.gy/nvl318

What happens when you put patients at the center of cancer research? Better options and better outcomes.

At our 4th annual Think Tank on Advancing Precision Medicine in Rare Cancers, experts in precision oncology explored how clinical trials are evolving from one-size-fits-all approaches to patient-centric models.

Watch Dr. Razelle Kurzrock, Dr. Young Kwang Chae, TCF CEO Jim Palma, and Dr. Jens Rueter discuss how precision medicine, flexible trial designs, and real-world data can make trials more accessible, faster, and more relevant for rare cancer patients.

🔗 From Drug Centric to Patient-Centric Precision Medicine & Immunotherapy Trials in Rare Cancers: https://targetcancer.short.gy/SsLIep